Navidea Biopharma (NAVB) Misses Q3 EPS by 1c

Navidea Biopharma (NYSE: NAVB) reported Q3 EPS of ($0.05), $0.01 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $3.98 million versus the consensus estimate of $2.78 million.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

You May Also Be Interested In

• The tech crown switches hands: Apple dethrones Nvidia as $4 trillion king
• Freedom Broker Upgrades Morgan Stanley (MS) to Buy
• DB cautious on cruise stocks as fundamentals “not as clear as bulls believe”